Curia adopts Berkeley Lights platform to accelerate, expand antibody-based drug discovery

By The Science Advisory Board staff writers

June 8, 2022 -- Contract research, development, and manufacturing organization Curia has adopted Berkeley Lights’ platform to accelerate and expand its antibody-based drug discovery capabilities.

The Beacon Optofluidic system and workflow from Berkeley Lights provides a seamless and comprehensive portfolio of state-of-the-art technologies for rapid progression of client antibody programs, addressing the earliest stage of discovery, through maturation and development, to manufacture new drugs and final drug products under good manufacturing practice (GMP).

"Speed counts in drug discovery, so the ability to conduct high-throughput, single-cell experiments is a game changer, enabling abundant and diverse leads," said Christopher Conway, president of R&D at Curia. "Advanced technologies such as the Berkeley Lights platform are revolutionizing antibody discovery, tackling key pain points that confront innovators, such as long timelines and limited number of sequences."

Integrity Bio, LakePharma become Curia
Curia (formerly AMRI) announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand.
Curia unveils mRNA solution
Curia, a contract research, development, and manufacturing organization, unveiled its mRNA solution. The new offering includes discovery, process development,...
Curia finalizes LakePharma acquisition
Curia has finalized its acquisition of LakePharma, a privately held biologics drug discovery, clinical research, and manufacturing organization.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter